ICICI Securities has issued a buy rating on Jyothy Labs with a target price of ₹310 in its research report dated May 05, 2026. According to the brokerage's analysis, the stock could trade at a 24x P/E multiple of March 2028E at the target price. The recommendation reflects confidence in the company's volume-led recovery strategy and long-term market positioning.
Jyothy Labs' Q4FY26 performance reflects a robust, volume-led recovery, validating management's strategy to defend and expand market share. As reported by ICICI Securities, the company achieved strong volume growth of ~11%, though this came at the expense of profitability. The brokerage views this near-term margin squeeze as a strategic investment in long-term market positioning, with the structural volume momentum largely in place.
The research firm has cut FY27 EPS estimates by 5.7% to reflect margin pressure. According to ICICI Securities, the company is expected to deliver revenue/EBITDA/PAT CAGR of 9.8%/15.7%/19.5% over FY26-28E. Despite measured earnings compounding until price hikes are fully absorbed and input costs stabilise, the structural volume momentum remains intact.
Jyothy Labs' expanding distribution footprint across modern trade (MT) and quick commerce (QC) has successfully secured a wider and resilient revenue base. As reported by ICICI Securities, the company remains debt-free with a cash chest of ~₹10 billion and is actively evaluating M&A targets. The brokerage expects JYL to deliver operating leverage once the commodity cycle normalises, supporting the positive investment thesis.
